AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8392282 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2.0 mg
Number of subjects: 72
Study 8392282 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 1.5 mg (intravenous)
Number of subjects: 72
Study 8392282 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat 1.0 mg (intravenous)
Number of subjects: 72
Study 8392282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral or intravenous)
Number of subjects: 72
Study 3946263 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training (42 to 60% of baseline VO2 max, average heart rate 102 to 122 beats/min)
Number of subjects: 64
Study 3946263 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (63 to 81% of baseline VO2 max, average heart rate 128 to 148 beats/min)
Number of subjects: 64
Study 3946263 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 64
Study 31202749 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ESS
Number of subjects: 44
Study 31202749 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-derived plaque characteristics
Number of subjects: 44
Study 31202749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ESS
Number of subjects: 44
Study 31202749 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque burden
Number of subjects: 44
Study 31202749 — intervention group
Group type: COMPARATOR
Intervention: IVUS-derived plaque characteristics with ESS
Number of subjects: 44
Study 31202749 — intervention group
Group type: COMPARATOR
Intervention: OCT variables and ESS
Number of subjects: 44
Study 29460547 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus octenidine
Number of subjects: 10
Study 27412269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubaramure program (food rations, health service promotion, behavior change communication)
Number of subjects: 0
Study 27412269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubaramure program
Number of subjects: 0
Study 24671453 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rabeprazole 20 mg twice daily for 5 days before ESD
Number of subjects: 120
Study 24671453 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily for 5 days before ESD
Number of subjects: 120
Study 24671453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric pH measurement
Number of subjects: 120
Study 23678499 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visiting programme targeting infant attachment
Number of subjects: 120
Study 20832103 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 143
Study 20832103 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 143
Study 19062727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy with paclitaxel (175 mg/m2) and epirubicin (60 mg/m2) every two weeks
Number of subjects: 101
Study 19062727 — intervention group
Group type: COMPARATOR
Intervention: Regular chemotherapy with paclitaxel (175 mg/m2) and epirubicin (60 mg/m2) every three weeks
Number of subjects: 101
Study 19062727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy
Number of subjects: 101
Study 19062727 — intervention group
Group type: COMPARATOR
Intervention: Regular chemotherapy
Number of subjects: 101
Study 15452681 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine with low dose methamphetamine (15 mg)
Number of subjects: 0
Study 15452681 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine with high dose methamphetamine (30 mg)
Number of subjects: 0
Study 15452681 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine without methamphetamine
Number of subjects: 0
Study 15452681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control) with low dose methamphetamine (15 mg)
Number of subjects: 0
Study 15452681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control) with high dose methamphetamine (30 mg)
Number of subjects: 0
Study 12593523 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate (BDP) suspension for nebulization 1,600 microg day(‐1) b.i.d. (n = 75)
Number of subjects: 151
Study 12593523 — intervention group
Group type: COMPARATOR
Intervention: Beclometasone dipropionate (BDP) spray 800 microg day(‐1) b.i.d. via metered-dose inhaler (MDI) plus spacer (n = 76)
Number of subjects: 151
Study 10578788 — intervention group
Group type: COMPARATOR
Intervention: Routine nipple care including an ointment (control group)
Number of subjects: 219
Study 10578788 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of nipple creams and other products (intervention group)
Number of subjects: 219
Study 8554224 — intervention group
Group type: EXPERIMENTAL
Intervention: 23‐polyvalent pneumococcal polysaccharide vaccine
Number of subjects: 30
Study 1677625 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 vaginal tablets
Number of subjects: 200
Study 1677625 — intervention group
Group type: COMPARATOR
Intervention: PGE2 vaginal pessaries
Number of subjects: 200
Study 1677625 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 vaginal tablets and PGE2 vaginal pessaries
Number of subjects: 200
Study 6129951 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (oral)
Number of subjects: 27
Study 6129951 — intervention group
Group type: COMPARATOR
Intervention: Propanolol (oral)
Number of subjects: 27
Study 6129951 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (IV)
Number of subjects: 27
Study 6129951 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (IV) and Metoprolol (IV) combined
Number of subjects: 27
Study 31704535 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training for balance control (2-week duration)
Number of subjects: 35
Study 31704535 — intervention group
Group type: COMPARATOR
Intervention: Usual exercises (waitlist control)
Number of subjects: 35
Study 31704535 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=25)
Number of subjects: 35
Study 30439785 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 16
Study 30439785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28549319 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (660nm, 200mW, continuous mode, time of irradiation: 32s, energy density: 4J/cm2, spot size: 0.5cm) applied immediately after FGG surgery and on days 1, 2, 4, and 7 post-surgery.
Number of subjects: 12
Study 28549319 — intervention group
Group type: COMPARATOR
Intervention: Laser-off control group receiving the same sequence of irradiation without laser.
Number of subjects: 12
Study 27083334 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg per day)
Number of subjects: 319
Study 27083334 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg per day)
Number of subjects: 319
Study 25163103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Treatment Study (MHTS) intervention including individual placement and support supported employment (IPS‐SE), systematic medication management (SMM), and additional behavioral‐health services (OBH)
Number of subjects: 2238
Study 25163103 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 2238
Study 21761999 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (single dose)
Number of subjects: 110
Study 21761999 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (infusion)
Number of subjects: 110
Study 19256733 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical story with distraction
Number of subjects: 76
Study 19256733 — intervention group
Group type: COMPARATOR
Intervention: Spoken story with distraction
Number of subjects: 76
Study 19256733 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical story with no distraction
Number of subjects: 76
Study 19256733 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoken story with no distraction
Number of subjects: 76
Study 16881500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ametop (amethocaine gel) applied to a digit for 30 minutes before capillary sampling
Number of subjects: 22
Study 16881500 — intervention group
Group type: COMPARATOR
Intervention: Control (digit on the opposing hand without Ametop)
Number of subjects: 22
Study 15023708 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 299
Study 15023708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 299
Study 11349825 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil/HCTZ, 16/12.5 mg once daily
Number of subjects: 328
Study 11349825 — intervention group
Group type: COMPARATOR
Intervention: Candesartan cilexetil/placebo, 16 mg once daily
Number of subjects: 328
Study 9475307 — intervention group
Group type: EXPERIMENTAL
Intervention: ARF‐treated porridge
Number of subjects: 30
Study 9475307 — intervention group
Group type: COMPARATOR
Intervention: Standard porridge liquefied with water
Number of subjects: 30
Study 7937827 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterium-labeled RRR-alpha-tocopherol
Number of subjects: 9
Study 7937827 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterium-labeled SRR-alpha-tocopherol
Number of subjects: 9
Study 7937827 — intervention group
Group type: COMPARATOR
Intervention: Difference in fractional disappearance rates between RRR and SRR in controls
Number of subjects: 9
Study 7937827 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol recycling
Number of subjects: 9
Study 3278436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0
Study 3278436 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppressive therapy
Number of subjects: 0
Study 30948278 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose aroma (5 drops of 40% rose aroma)
Number of subjects: 132
Study 30948278 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson relaxation technique
Number of subjects: 132
Study 30948278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rose aroma and Benson relaxation
Number of subjects: 132
Study 30948278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 132
Study 28358168 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 U BTX‐B
Number of subjects: 45
Study 28358168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 U BTX‐B
Number of subjects: 45
Study 28358168 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 U BTX‐B
Number of subjects: 45
Study 28358168 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 45
Study 25059736 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Number of subjects: 69
Study 25059736 — intervention group
Group type: COMPARATOR
Intervention: No graduated compression stockings (Control)
Number of subjects: 69
Study 23276469 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antiretroviral therapy
Number of subjects: 3085
Study 23276469 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 3085
Study 23276469 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 3085
Study 23276469 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 3085
Study 21576196 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone for 6 months
Number of subjects: 34
Study 21576196 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 34
Study 17526621 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training on sand
Number of subjects: 37
Study 17526621 — intervention group
Group type: COMPARATOR
Intervention: Plyometric training on grass
Number of subjects: 37
Study 14985966 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (2.25 microg/kg per min)
Number of subjects: 27
Study 14985966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (at least 0.025 microg/kg per min)
Number of subjects: 27
Study 14985966 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 27
Study 12467536 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.3 IU/kg) injected percutaneously every evening for ten days since the 1st postoperative day (POD)
Number of subjects: 50
Study 12467536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhGH treatment)
Number of subjects: 50
Study 12467536 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH group
Number of subjects: 50
Study 12467536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 9438269 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (250 ml 20%)
Number of subjects: 0
Study 9438269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7805666 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper arm cuff pressures applied randomly between 0 and 25 mmHg for 15 min
Number of subjects: 12
Study 7805666 — intervention group
Group type: EXPERIMENTAL
Intervention: Different forearm positions (-18, 0, 18, 36, 54 cm relative to heart level)
Number of subjects: 12
Study 2779970 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine in the irrigating fluid
Number of subjects: 39
Study 2779970 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine intracameral
Number of subjects: 39
Study 2779970 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 39
Study 788744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoxetine (10-20 mg b.d. for 7 days)
Number of subjects: 0
Study 788744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31221143 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 4 Health (G4H)
Number of subjects: 200
Study 31221143 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 200
Study 28662613 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified World Health Organization ORS (group A)
Number of subjects: 28
Study 28662613 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available ORS (DripDrop; group B)
Number of subjects: 28
Study 28662613 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 28
Study 26397431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse support during recovery
Number of subjects: 0
Study 23401566 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-delivered exercise intervention
Number of subjects: 307
Study 23401566 — intervention group
Group type: COMPARATOR
Intervention: Healthy aging, attentional control
Number of subjects: 307
Study 21616540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise (16.5 kcal/kg/week, three times a week during hospitalization)
Number of subjects: 0
Study 21616540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise
Number of subjects: 0
Study 21616540 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19803573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural congruence in treatment
Number of subjects: 272
Study 19803573 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced specialty referral model
Number of subjects: 272
Study 19803573 — intervention group
Group type: COMPARATOR
Intervention: Integrated primary care model
Number of subjects: 272
Study 16940452 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a mean maintenance dose of 0.31 mg/d in elderly GHD patients
Number of subjects: 48
Study 16940452 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a mean maintenance dose of 0.44 mg/d in younger GHD patients
Number of subjects: 48
Study 16940452 — intervention group
Group type: COMPARATOR
Intervention: Control group (elderly GHD patients)
Number of subjects: 48
Study 14525770 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (oral solution 2.5 mg/kg 3 times daily, or intravenous 200 mg daily)
Number of subjects: 304
Study 14525770 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (400 mg/d)
Number of subjects: 304
Study 14525770 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 304
Study 14525770 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 304
Study 14525770 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and fungal-free survival
Number of subjects: 304
Study 11380123 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 47
Study 11380123 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment in a plaster cast
Number of subjects: 47
Study 8981381 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Evoked Responses (AERs) using two-tone non-speech stimuli with temporal lags (TOT)
Number of subjects: 16
Study 8501990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Rehabilitation Evaluation System (CARES) Psychosocial Summary Scale
Number of subjects: 227
Study 8501990 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Status score
Number of subjects: 227
Study 8501990 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 227
Study 2960861 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretin (0, 25, or 50 mg/day for 8 weeks, followed by 25, 50, or 75 mg/day for optimal response)
Number of subjects: 8
Study 2960861 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretin
Number of subjects: 8
Study 30206079 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice, exercises and soft-tissue treatment plus manipulative therapy
Number of subjects: 238
Study 30206079 — intervention group
Group type: COMPARATOR
Intervention: Advice, exercises and soft-tissue treatment
Number of subjects: 238
Study 27257748 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation letters that paid attention to the development of AN
Number of subjects: 46
Study 27257748 — intervention group
Group type: EXPERIMENTAL
Intervention: More reflective and respectful letters
Number of subjects: 46
Study 24292991 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (1 g intravenously once daily for 4 days)
Number of subjects: 600
Study 24292991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 21295363 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg/day
Number of subjects: 40
Study 21295363 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg/day and Ramipril 10mg/day
Number of subjects: 40
Study 20394631 — intervention group
Group type: COMPARATOR
Intervention: C/BPO alone
Number of subjects: 80
Study 20394631 — intervention group
Group type: EXPERIMENTAL
Intervention: C/BPO + PDL treatment (wavelength 585 nm, energy fluence 3 J cm(‐2), pulse duration 0.35 ms, spot size 7 mm)
Number of subjects: 80
Study 18546664 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-present scene
Number of subjects: 0
Study 18546664 — intervention group
Group type: COMPARATOR
Intervention: Person-absent scene
Number of subjects: 0
Study 18546664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender discrimination task
Number of subjects: 0
Study 18546664 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces in the scene
Number of subjects: 0
Study 18546664 — intervention group
Group type: EXPERIMENTAL
Intervention: Object being fixated by the person in the scene
Number of subjects: 0
Study 16484109 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of loci
Number of subjects: 0
Study 16484109 — intervention group
Group type: COMPARATOR
Intervention: Link method
Number of subjects: 0
Study 16484109 — intervention group
Group type: COMPARATOR
Intervention: Rehearsal method
Number of subjects: 0
Study 12100223 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg oral
Number of subjects: 16
Study 12100223 — intervention group
Group type: EXPERIMENTAL
Intervention: ergotamine 0.25 mg i.v.
Number of subjects: 16
Study 12100223 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg oral + ergotamine 0.25 mg i.v.
Number of subjects: 16
Study 12100223 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 10543758 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-based regimens
Number of subjects: 516
Study 10543758 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-metronidazole regimen with omeprazole
Number of subjects: 516
Study 10543758 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-based regimen
Number of subjects: 516
Study 10543758 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility testing
Number of subjects: 516
Study 7872936 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low back pain patients
Number of subjects: 20
Study 7872936 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 2171383 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS3,3 at 50 mA
Number of subjects: 22
Study 2171383 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS3,2 at 50 mA
Number of subjects: 22
Study 2171383 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS3,3 and DBS3,2 at 20 and 30 mA
Number of subjects: 22
Study 318951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 25 mg and Aspirin 325 mg (PA-L)
Number of subjects: 98
Study 318951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg and Aspirin 650 mg (PA-H)
Number of subjects: 98
Study 318951 — intervention group
Group type: COMPARATOR
Intervention: 650 mg of Aspirin (A650)
Number of subjects: 98
Study 318951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 98
Study 30084873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach to Mendelian randomization with multiple pleiotropic variants
Number of subjects: 0
Study 30979460 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus with reduced-dose corticosteroids
Number of subjects: 150
Study 30979460 — intervention group
Group type: COMPARATOR
Intervention: Prolonged-release tacrolimus with standard-dose corticosteroids
Number of subjects: 150
Study 30979460 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus
Number of subjects: 150
Study 28166457 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug (exact dosage and duration not specified)
Number of subjects: 0